Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.17%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.67 per share when it actually produced earnings of $0.75, delivering a surprise of +11.94%.Over the last four ...

财务表现 - 2025年Q1营业收入达6.89亿元，同比增长0.30%，环比增长37.30% [2][3] - 归属于上市公司股东的净利润1.10亿元，同比下降19.88% [3] - 经营活动产生的现金流量净额3721.92万元，同比下降51.79% [3] - 生命科学板块收入3.54亿元，同比增长1.06%，环比增长53.28% [3] - 医疗创新板块收入3.32亿元，同比下降0.61%，环比增长24.26% [3] 业务驱动因素 - 非存储新产业收入占比44%，同比增长13.92%，环比增长27.35%，采浆耗材、用药自动化、实验室耗材和仪器等业务持续增长 [4] - 国内市场收入4.82亿元，同比下降3.35%，环比增长54.98%，场景方案交互和定制能力提升，品牌力增强 [4] - 海外市场收入2.04亿元，同比增长9.88%，环比增长8.99%，本土化布局强化，多品类发展动能显现 [4] 战略布局 - 在细胞治疗领域推出智能全自动细胞培养工作站，落地吉美瑞生等多家机构 [5] - 血液产业方面通过AI+智慧血液管理系统提升采供血效率，加速产学研共创 [5]